Sanofi: FDA Approves Sarclisa With Carfilzomib, Dexamethasone for Relapsed or Refractory Multiple Myeloma
April 01 2021 - 1:37AM
Dow Jones News
By Giulia Petroni
Sanofi SA said late Wednesday that the U.S. Food and Drug
Administration has approved Sarclisa, or isatuximab, in combination
with carfilzomib and dexamethasone for patients with relapsed or
refractory multiple myeloma.
The French pharmaceutical company said the treatment is for
adult patients with RRMM who have already received one to three
prior therapies.
According to the Phase 3 Ikema study, the Sarclisa combination
treatment allows for the reduction of risk of disease progression
or death by 45%, Sanofi said.
The FDA had previously approved the Sarclisa regimen for the
treatment of adults with RRMM who have received at least two prior
therapies.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
April 01, 2021 01:22 ET (05:22 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024
